A Clinical Study of MIL62 in Primary Membranous Nephropathy

  • STATUS
    Recruiting
  • End date
    Oct 16, 2025
  • participants needed
    120
  • sponsor
    Beijing Mabworks Biotech Co., Ltd.
Updated on 16 June 2022

Summary

This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group. Tolerance to MIL62 was evaluated within 4 weeks after the first administration. If the overall safety is determined by the investigator and sponsor to be tolerable to MIL62, phase II enrollment will be initiated.

The second stage was also randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups according to the ratio of 1:1:1, 30 subjects in each group, to evaluate the efficacy of MIL62 and cyclosporine in the treatment of primary membranous nephropathy. Eligible subjects in both phases received treatment and follow-up for a total of 104 weeks. The 76-week overall response rate was the primary endpoint.

Details
Condition Primary Membranous Nephropathy
Treatment cyclosporine, MIL62
Clinical Study IdentifierNCT05398653
SponsorBeijing Mabworks Biotech Co., Ltd.
Last Modified on16 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult patients, ≥18 years of age
Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening;
Best support for 3 months before the screening and above, 24 hours urinary protein 5 g or higher, or screening best support treatment before 6 months or more, 24 hours urinary protein > 3.5 g, and urine protein decreased 50% or less, or if it always has the best support after a full course of treatment, 24 hours urinary protein is still more than standard after confirmed by the researchers can into the group
eGFR ≥40 mL/min/1.73m^2 or qualified endogenous creatinine clearance ≥40 mL/min/1.73m^2 based on 24-hour urine collection during screening;
Sufficient organ function
Able and willing to provide written informed consent and to comply with the study protocol

Exclusion Criteria

Participants with a secondary cause of MN;
Cyclosporine resistance;
Urine protein decreased by > 50% within 6 months before screening;
Received treatment drugs for membranous nephropathy;
Concomitant with other serious diseases;
Received live vaccination, major surgery (other than diagnostic), and participated in other clinical trials within 28 days prior to receiving the first study drug;Central nervous system metastasis;
Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C(including HBsAg,HBcAb positive with abnormal HBV DNA or HCV RNA )
Those who have a clear history of tuberculosis or have received anti-tuberculosis treatment;
Other exclusion criteria may apply;
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note